Data obtained from patients’ follow-up (minimum of 48 months) with PSA measurements, MRI exams (given the high MRI negative predictive value) with application of ML techniques and targeted biopsy results (areas not harboring prostate cancer), integrated to information obtained from body fluid examinations, gene profile and molecular data might be exploited through the application of a network-based method, to obtain meaningful data not solely on cancer cell, rather on normal tissue in order to perform tumor screening and early diagnosis. The gene discussed is KLK3; the disease is Familial prostate cancer.